Blacksburg, VA, United States
Blacksburg, VA, United States

Time filter

Source Type

GERMANTOWN, Md., May 15, 2017 /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in the engineering and industrialization of biology to improve the quality of life and health of the planet, today announced management will participate at the Bank of America Merrill Lynch 2017 Healthcare Conference at Encore at the Wynn, Las Vegas, Nevada. About Intrexon Corporation:  Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn.


News Article | May 18, 2017
Site: www.prnewswire.com

Dr. Carnegie-Brown joins Oxitec with over 25 years leadership in the life science and health science industries. This includes strategic and operational experience in agrochemicals, drug development, contract manufacturing and drug delivery businesses.  Prior to joining Oxitec, he was Chief Executive Officer of Glide Technologies and led the business to develop a proven therapeutic delivery platform, generate positive clinical results, and build a scalable manufacturing line.  Before joining Glide Dr. Carnegie-Brown was General Manager of Zeneca's Agrochemical business in the United Kingdom and Ireland where he developed and implemented a cutting edge value chain strategy and drove transformation toward an organization attuned to consumers.  He also previously served as Chief Executive Officer of Evolutec plc, a biological drug development business.  Dr. Carnegie-Brown received a Ph.D. in Applied Biology with a specialty in pesticide resistance from Manchester University. Concurrent with Dr. Carnegie-Brown's appointment, Mr. Parry will move to a broader corporate role to support numerous functions abroad with specific responsibility for developing and expanding Intrexon's interests and business opportunities in EMEA.  His business acumen, strong communication skills, and ability to engage at all levels of business from government to corporations to consumers will be a key asset to Intrexon. "It has been a real privilege to lead Oxitec over the last few years and to help develop such a promising technology into a truly operational solution that is much needed around the world. I now look forward to supporting the growth of Intrexon's broader business," said Mr. Parry. Randal J. Kirk, Chairman and Chief Executive Officer of Intrexon, commented, "We welcome Mark at the helm of Oxitec, the leading engineered insect capability in the world, and its exemplary team of scientists who are doing so much to address some of the most pressing needs in human disease vector control and crop protection against insect pests.  And we welcome Hadyn, who so capably led Oxitec to its world leading position, to a role of even greater responsibility as he helps us to expand Intrexon's reach and penetration across multiple opportunities offering similar impact." About Oxitec  Oxitec is a pioneer in using genetic engineering to control insect pests that spread disease and damage crops, and was founded in 2002 as a spinout from Oxford University (UK).  Oxitec is a subsidiary of Intrexon Corporation (NYSE: XON), which engineers biology to help solve some of the world's biggest problems.  Follow us on Twitter at @Oxitec. About Intrexon Corporation:   Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. Trademarks  Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners. Safe Harbor Statement  Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. For more information regarding Intrexon Corporation, contact: To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intrexon-appoints-dr-mark-carnegie-brown-as-ceo-of-oxitec-300460247.html


News Article | May 24, 2017
Site: www.prnewswire.com

About Intrexon Corporation: Intrexon Corporation (NYSE: XON) is Powering the Bioindustrial Revolution with Better DNA™ to create biologically-based products that improve the quality of life and the health of the planet.  Intrexon's integrated technology suite provides its partners across diverse markets with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells. We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com or follow us on Twitter at @Intrexon, on Facebook, and LinkedIn. Trademarks Intrexon, Powering the Bioindustrial Revolution with Better DNA, and Better DNA are trademarks of Intrexon and/or its affiliates. Other names may be trademarks of their respective owners. Safe Harbor Statement Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/intrexon-to-present-at-upcoming-investor-and-industry-conferences-300463099.html


News Article | April 25, 2017
Site: marketersmedia.com

Celiac Disease Pipeline Market Review, H1 2017 report provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal).This report find and recognize significant and varied types of therapeutics under development for Celiac Disease (Gastrointestinal).Pune, India - April 25, 2017 /MarketersMedia/ — ReportsnReports.com latest Pharmaceutical and Healthcare disease pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides an overview of the Celiac Disease (Gastrointestinal) pipeline landscape. Browse 35 Tables and Figures, 13 Company Profiles, spread across 82 pages available @ http://www.reportsnreports.com/contacts/discount.aspx?name=958314. Celiac disease is an autoimmune disorder caused by an immune response to wheat protein gluten. Symptoms include weight loss, vomiting, abdominal bloating, abdominal pain and persistent diarrhea. Risk factors include lupus, rheumatoid arthritis, type 1 diabetes, autoimmune liver disease, Sjogrens syndrome and Turner syndrome. Treatment includes steroids such as betamethasone and prednisolone. Further the treatment regime also involves adhering to strict gluten free diet. Celiac Disease - Companies Involved in Therapeutics Development Amgen Inc, Amyra Biotech AG, Calypso Biotech SA, Circle33 LLC, enGene Inc, F. Hoffmann-La Roche Ltd, Glenmark Pharmaceuticals Ltd, ImmusanT Inc, Innovate Biopharmaceuticals Inc, Intrexon Corp, Sanofi, Takeda Pharmaceutical Company Ltd, Zedira GmbH Report Highlights Pharmaceutical and Healthcare latest pipeline guide Celiac Disease - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Celiac Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Celiac Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 3, 5, 10 and 5 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively. Celiac Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Order a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=958314. Scope of the report: - The pipeline guide provides a snapshot of the global therapeutic landscape of Celiac Disease (Gastrointestinal). - The pipeline guide reviews pipeline therapeutics for Celiac Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Celiac Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Celiac Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Celiac Disease (Gastrointestinal) List of Tables Number of Products under Development for Celiac Disease, H1 2017 Number of Products under Development by Companies, H1 2017 Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Number of Products under Development by Universities/Institutes, H1 2017 Products under Development by Companies, H1 2017 Products under Development by Companies, H1 2017 (Contd..1), H1 2017 Products under Development by Universities/Institutes, H1 2017 Number of Products by Stage and Target, H1 2017 Number of Products by Stage and Mechanism of Action, H1 2017 Number of Products by Stage and Route of Administration, H1 2017 Number of Products by Stage and Molecule Type, H1 2017 Celiac Disease - Pipeline by Amgen Inc, H1 2017 Celiac Disease - Pipeline by Amyra Biotech AG, H1 2017 Celiac Disease - Pipeline by Calypso Biotech SA, H1 2017 Celiac Disease - Pipeline by Circle33 LLC, H1 2017 Celiac Disease - Pipeline by enGene Inc, H1 2017 About Us ReportsnReports.com is your single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets. Contact Info:Name: Ritesh TiwariEmail: sales@reportsandreports.comOrganization: ReportsnReports.comAddress: Magarpatta City, Pune, Maharashtra, IndiaPhone: +1-888-391-5441Source URL: http://marketersmedia.com/h1-2017-celiac-disease-gastrointestinal-pipeline-market-landscape-review-report/189602For more information, please visit http://www.reportsnreports.com/reports/958314-celiac-disease-pipeline-review-h1-2017.htmlSource: MarketersMediaRelease ID: 189602


Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of GenVec, Inc. (“GenVec”) (NASDAQ:GNVC) common stock in connection with the proposed acquisition of GenVec by Intrexon Corporation and Intrexon GV Holding, Inc. (collectively, “Intrexon”) announced on January 24, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against GenVec, its Board of Directors (the “Board”), and Intrexon, is captioned Parshall v. GenVec, Inc., Case No. 1:17-cv-00338-GMS (D. Del.). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at info@rl-legal.com; or at http://rigrodskylong.com/contact-us/. On January 24, 2017, GenVec entered into an agreement and plan of merger (the “Merger Agreement”) with Intrexon.  Pursuant to the Merger Agreement, GenVec shareholders will receive 0.297 shares of Intrexon common stock, plus one contingent payment right (the “Proposed Transaction”). Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission on March 17, 2017.  The Registration Statement, which recommends that GenVec stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to GenVec’s financial projections, the analyses performed by GenVec’s financial advisor, and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of GenVec common stock. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.


Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of GenVec, Inc. (“GenVec”) (NASDAQ:GNVC) common stock in connection with the proposed acquisition of GenVec by Intrexon Corporation and Intrexon GV Holding, Inc. (collectively, “Intrexon”) announced on January 24, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against GenVec, its Board of Directors (the “Board”), and Intrexon, is captioned Parshall v. GenVec, Inc., Case No. 1:17-cv-00338-GMS (D. Del.). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at info@rl-legal.com; or at http://rigrodskylong.com/contact-us/. On January 24, 2017, GenVec entered into an agreement and plan of merger (the “Merger Agreement”) with Intrexon.  Pursuant to the Merger Agreement, GenVec shareholders will receive 0.297 shares of Intrexon common stock, plus one contingent payment right (the “Proposed Transaction”). Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission on March 17, 2017.  The Registration Statement, which recommends that GenVec stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to GenVec’s financial projections, the analyses performed by GenVec’s financial advisor, and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of GenVec common stock. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.


Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of GenVec, Inc. (“GenVec”) (NASDAQ:GNVC) common stock in connection with the proposed acquisition of GenVec by Intrexon Corporation and Intrexon GV Holding, Inc. (collectively, “Intrexon”) announced on January 24, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against GenVec, its Board of Directors (the “Board”), and Intrexon, is captioned Parshall v. GenVec, Inc., Case No. 1:17-cv-00338-GMS (D. Del.). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at info@rl-legal.com; or at http://rigrodskylong.com/contact-us/. On January 24, 2017, GenVec entered into an agreement and plan of merger (the “Merger Agreement”) with Intrexon.  Pursuant to the Merger Agreement, GenVec shareholders will receive 0.297 shares of Intrexon common stock, plus one contingent payment right (the “Proposed Transaction”). Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission on March 17, 2017.  The Registration Statement, which recommends that GenVec stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to GenVec’s financial projections, the analyses performed by GenVec’s financial advisor, and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of GenVec common stock. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.


Rigrodsky & Long, P.A. announces that it has filed a class action complaint in the United States District Court for the District of Delaware on behalf of holders of GenVec, Inc. (“GenVec”) (NASDAQ:GNVC) common stock in connection with the proposed acquisition of GenVec by Intrexon Corporation and Intrexon GV Holding, Inc. (collectively, “Intrexon”) announced on January 24, 2017 (the “Complaint”).  The Complaint, which alleges violations of the Securities Exchange Act of 1934 against GenVec, its Board of Directors (the “Board”), and Intrexon, is captioned Parshall v. GenVec, Inc., Case No. 1:17-cv-00338-GMS (D. Del.). If you wish to discuss this action or have any questions concerning this notice or your rights or interests, please contact plaintiff’s counsel, Seth D. Rigrodsky or Gina M. Serra at Rigrodsky & Long, P.A., 2 Righter Parkway, Suite 120, Wilmington, DE 19803, by telephone at (888) 969-4242; by e-mail at info@rl-legal.com; or at http://rigrodskylong.com/contact-us/. On January 24, 2017, GenVec entered into an agreement and plan of merger (the “Merger Agreement”) with Intrexon.  Pursuant to the Merger Agreement, GenVec shareholders will receive 0.297 shares of Intrexon common stock, plus one contingent payment right (the “Proposed Transaction”). Among other things, the Complaint alleges that, in an attempt to secure shareholder support for the Proposed Transaction, defendants issued materially incomplete disclosures in a registration statement (the “Registration Statement”) filed with the United States Securities and Exchange Commission on March 17, 2017.  The Registration Statement, which recommends that GenVec stockholders vote in favor of the Proposed Transaction, omits material information necessary to enable shareholders to make an informed decision as to how to vote on the Proposed Transaction, including material information with respect to GenVec’s financial projections, the analyses performed by GenVec’s financial advisor, and potential conflicts of interest.  The Complaint seeks injunctive and equitable relief and damages on behalf of holders of GenVec common stock. If you wish to serve as lead plaintiff, you must move the Court no later than June 16, 2017.  A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.  Any member of the proposed class may move the Court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member. Rigrodsky & Long, P.A., with offices in Wilmington, Delaware and Garden City, New York, regularly prosecutes securities fraud, shareholder corporate, and shareholder derivative litigation on behalf of shareholders in state and federal courts throughout the United States.


News Article | March 2, 2017
Site: www.businesswire.com

WALTHAM, Mass.--(BUSINESS WIRE)--OvaScienceSM (NASDAQ: OVAS), a global fertility company focused on the discovery, development and commercialization of new treatment options, today reported financial results and provided a business update for the fourth quarter and year ended December 31, 2016. “We are entering 2017 with continued confidence in our portfolio of potentially transformative fertility treatments and a strong belief in the potential of our EggPC platform to help women and couples build the families they deserve,” said Michelle Dipp, M.D., Ph.D., Executive Chair and Co-Founder of OvaScience. “In 2016, we achieved criteria indicative of developmental competence in EggPC cell-derived bovine and human eggs, an important step in the preclinical development of OvaTure, and we are on track to successfully fertilize a bovine EggPC cell-derived egg by year-end,” added Christophe Couturier, Chief Financial Officer. “We are also pleased to have enrolled the first 50 patients in our company-sponsored trial of OvaPrime, and to have started performing the first biopsies and reintroductions. With these milestones in hand, we remain on track to report initial data on our first 20 patients from this study by year-end. We are sufficiently funded to support the preclinical development of OvaTure and clinical development of OvaPrime into the first quarter of 2019.” OvaTureSM Treatment: The Company today reviewed progress for OvaTure, its potential next-generation in vitro fertilization (IVF) treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections by maturing egg precursor (EggPC SM) cells into eggs in vitro. There are a choreographed series of events that occur during egg maturation to prepare an egg for fertilization. Collectively, these can be described as developmental competence. Together with its partner, Intrexon Corporation (NYSE: XON), OvaScience has developed an in vitro cell culture process that has produced bovine and human eggs derived from EggPC cells that exhibit genetic, morphological and functional criteria of developmental competence during various phases of maturation. These criteria include: chromosomal segregation; an increase in cytoplasmic volume; the appearance of germinal vesicles, polar bodies and zona pellucida structures; and a positive brilliant cresyl blue (BCB) test. Fertilization studies for bovine EggPC-cell derived eggs are underway and OvaScience and Intrexon expect to successfully fertilize a bovine EggPC-derived egg by year-end. OvaScience will continue to work with its clinical partners to develop a repeatable and robust process for the maturation of eggs derived from human EggPC cells and to secure authorization to fertilize human EggPC cell-derived eggs and embryos by the end of the first half of 2018. OvaPrimeSM Treatment: The Company announced milestone achievements for OvaPrime, a potential fertility treatment that could enable a woman who makes too few or no eggs to increase her egg reserve. In December 2016, OvaScience announced its decision to continue the development of OvaPrime. OvaScience is currently evaluating OvaPrime in a prospective, blinded, randomized and controlled Company-sponsored trial, which is designed to assess the safety of OvaPrime and changes in a patient’s hormone levels and follicular development as measured by ultrasound. The trial will enroll 70 women with either diminished ovarian reserve (DOR) or primary ovarian insufficiency (POI). To date, the Company has enrolled 50 patients and expects to enroll an additional 20 women by the end of the first half of 2017. OvaScience recently completed the first biopsies and reintroductions in this ongoing clinical trial in Canada. The Company remains on track to announce initial data from the first 20 patients, including six months of post-EggPC reintroduction safety data, by year-end. AUGMENT SM Treatment: The Company maintained its commercial footprint for AUGMENT, a treatment designed to improve egg health and with that, IVF success rates, by using mitochondria from a woman’s own EggPC cells during IVF. In December 2016, the Company announced that it will continue to make AUGMENT available to patients at clinics in Canada and Japan and will expand regionally on a limited basis as appropriate. Also announced in December 2016, the Company is reassessing its clinical development strategy for AUGMENT, including its planned multi-center clinical trial and the ongoing IVI-sponsored study in Valencia, Spain. Separately, OvaScience will meet with the U.S. Food and Drug Administration (FDA) in the first half of 2017, as part of its ongoing exploration of potential entry into the U.S. market. The Company expects to achieve the following milestones in 2017: At December 31, 2016, OvaScience had cash, cash equivalents and short-term investments of $114.4 million. OvaScience expects one-time cash expenditures of approximately $5.7 million to $6.5 million over 2017 and 2018 related to actions resulting from the corporate restructuring announced in December 2016. The Company may also incur further restructuring charges related to the restructuring plan. OvaScience’s operating cash burn for 2017 is expected to be between $45 million and $50 million, which excludes these one-time cash expenditures. OvaScience anticipates that it will have sufficient funds, without additional financing, to support its operating plan into the first quarter of 2019. Conference Call OvaScience will host a conference call at 4:30 p.m. ET today, Thursday, March 2, 2017, to discuss these financial results and provide an update on the Company. The conference call may be accessed by dialing +1-888-424-8151 for U.S. callers and +1-847-585-4422 for international callers five minutes prior to the start of the call and providing the passcode 7862456. Additionally, the live, listen-only webcast of the conference call can be accessed by visiting the Investors section of the Company’s website at www.ovascience.com. A replay of the conference call will be available from 7:00 p.m. ET on Thursday, March 2, 2017 through 11:59 p.m. ET on Thursday, March 9, 2017, and may be accessed by visiting OvaScience’s website or by dialing +1-888-843-7419 for U.S. callers and +1-630-652-3042 for international callers. The replay access code is 7862456#. About OvaScience OvaScienceSM, Inc. (NASDAQ: OVAS) is a global fertility company dedicated to improving treatment options for women around the world. OvaScience is discovering, developing and commercializing new fertility treatments because it believes women deserve more options. Each OvaScience treatment is based on the Company’s proprietary technology platform that leverages the breakthrough discovery of egg precursor (EggPCSM) cells – immature egg cells found inside the protective ovarian lining. OvaScience is developing OvaTureSM, a potential next-generation IVF treatment that could help a woman produce healthy, young, fertilizable eggs without hormone injections and OvaPrimeSM, which could increase a woman’s egg reserve. OvaScience’s AUGMENTSM treatment, a fertility option designed to improve IVF success rates, is available in certain IVF clinics in select international regions. OvaScience treatments are not available in the U.S. For more information, visit www.ovascience.com. Forward-Looking Statements This press release includes forward-looking statements about the Company’s plans for the OvaPrime treatment, OvaTure treatment and AUGMENT treatment, including statements relating to the Company’s plans to fertilize a bovine EggPC cell-derived egg by year-end; to complete enrollment of all 70 patients in the ongoing Canadian study of OvaPrime by the end of the first half of 2017; to complete biopsies in all patients in the ongoing Canadian study of OvaPrime by year-end; to present initial data from 20 OvaPrime patients, including six months of post-EggPC reintroduction safety data, by year-end; availability of sufficient funding to support the preclinical development of OvaTure and clinical development of OvaPrime into the first quarter of 2019; the Company’s further efforts on human egg maturation, the Company’s plans to work with its clinical partners in pursuit of its goals to develop a repeatable and robust process for the maturation of eggs derived from human EggPC cells and to secure authorization to fertilize human EggPC cell-derived eggs and embryos by the end of the first half of 2018; and the Company’s plans to meet with the U.S. Food and Drug Administration in the first half of 2017. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including risks related to: the science underlying our treatments (including the OvaPrime, OvaTure and AUGMENT treatments), which is unproven; our ability to obtain regulatory approval or licenses where necessary for our treatments; our ability to develop our treatments on the timelines we expect, if at all; our ability to commercialize our treatments, on the timelines we expect, if at all; as well as those risks more fully discussed in the “Risk Factors” section of our most recently filed Quarterly Report on Form 10-Q and/or Annual Report on Form 10-K. The forward-looking statements contained in this press release reflect our current views with respect to future events. We anticipate that subsequent events and developments will cause our views to change. However, while we may elect to update these forward-looking statements in the future, we specifically disclaim any obligation to do so. These forward-looking statements should not be relied upon as representing our view as of any date subsequent to the date hereof.


News Article | February 16, 2017
Site: news.yahoo.com

Randal Kirk, Intrexon CEO chairman & CEO, discusses the biotech company's advances in genetic engineering.

Loading Intrexon collaborators
Loading Intrexon collaborators